Marizyme, Inc. (MRZM)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Oct 2, 2025
Marizyme Revenue
Marizyme had revenue of $183.42K in the twelve months ending September 30, 2024, down -68.96% year-over-year. In the year 2023, Marizyme had annual revenue of $645.81K with 176.60% growth.
Revenue (ttm)
183.42K
Revenue Growth
-68.96%
P/S Ratio
0.00
Revenue / Employee
14.11K
Employees
13
Market Cap
132.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 645.81K | 412.33K | 176.60% |
| Dec 31, 2022 | 233.49K | 23.21K | 11.04% |
| Dec 31, 2021 | 210.28K | 13.14K | 6.67% |
| Dec 31, 2020 | 197.14K | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Marizyme News
- 1 year ago - Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ - GlobeNewsWire
- 2 years ago - Marizyme CEO Delivers Business Update - GlobeNewsWire
- 2 years ago - Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ - GlobeNewsWire
- 2 years ago - Marizyme Announces IP Developments for DuraGraft® and Its Pipeline Products - GlobeNewsWire
- 4 years ago - Marizyme Announces Allowance of Patent Application for Flagship Product DuraGraft by United States Patent and Trademark Office - GlobeNewsWire
- 4 years ago - Marizyme Announces the Closing of My Health Logic Acquisition Along With Initial Financing - GlobeNewsWire
- 4 years ago - Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress - GlobeNewsWire
- 4 years ago - Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories - GlobeNewsWire